Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Expert Review of Anticancer Therapy

• Publication date

  2014-09-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.1586/14737140.2014.952287PMID 25148289
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Correlation of immune responses and survival in a phase II study of belagenpumatucel-L in non-small cell lung cancer.

  2016cited by this paper
• Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (anti-PDL1) in non-small cell lung cancer (NSCLC): update from a phase Ia study.

  2015cited by this paper
• Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1–selected patients with non-small cell lung cancer (NSCLC).

  2015cited by this paper
• Results of the phase IIb part of TIME study evaluating TG4010 immunotherapy in stage IV non-small cell lung cancer (NSCLC) patients receiving first line chemotherapy.

  2015cited by this paper
• Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.

  2014cited by this paper
• Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results.

  2013cited by this paper
• Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer

  2013cited by this paper
• Programmed death-ligand 1 (PD-L1) expression in various tumor types

  2013cited by this paper
• Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial).

  2013cited by this paper
• Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

  2013cited by this paper
• Efficacy and Safety of Retreatment with Ipilimumab in Patients with Pretreated Advanced Melanoma Who Progressed after Initially Achieving Disease Control

  2013cited by this paper
• Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial.

  2013cited by this paper
• A phase III comparative study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus docetaxel in patients with previously treated advanced or metastatic squamous cell non-small cell lung cancer (NSCLC).

  2013cited by this paper
• Preclinical evaluation of racotumomab, an anti-idiotype monoclonal antibody to N-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer

  2012cited by this paper
• Personalized targeted therapy in advanced non–small cell lung cancer

  2012cited by this paper
• Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

  2012cited by this paper
• TIME: A phase IIb/III randomized, double-blind, placebo-controlled study comparing first-line therapy with or without TG4010 immunotherapy product in patients with stage IV non-small cell lung cancer (NSCLC).

  2012cited by this paper
• Cancer immunoediting by the innate immune system in the absence of adaptive immunity

  2012cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer.

  2012influential reference
• CA184-104: Randomized, multicenter, double-blind, phase III trial comparing the efficacy of ipilimumab (Ipi) with paclitaxel/carboplatin (PC) versus placebo with PC in patients (pts) with stage IV/recurrent non-small cell lung cancer (NSCLC) of squamous histology.

  2012cited by this paper
• CA184-156: Randomized, multicenter, double-blind, phase III trial comparing the efficacy of ipilimumab (Ipi) plus etoposide/platinum (EP) versus placebo plus EP in patients (Pts) with newly diagnosed extensive-stage disease small cell lung cancer (ED-SCLC).

  2012cited by this paper
• Randomized, Double-Blind, Placebo-Controlled Phase II Study of Single-Agent Oral Talactoferrin in Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer That Progressed After Chemotherapy

  2012cited by this paper
• Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

  2012cited by this paper
• Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

  2012cited by this paper
• Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development.

  2012cited by this paper
• High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation

  2011cited by this paper
• Role of PD-1 in regulating T-cell immunity.

  2011cited by this paper
• Cancer immunology.

  2011cited by this paper
• INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer

  2011cited by this paper
• A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Oral Talactoferrin in Combination with Carboplatin and Paclitaxel in Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer

  2011cited by this paper
• Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis

  2011cited by this paper
• Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy.

  2011cited by this paper
• Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens

  2011cited by this paper
• Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

  2011cited by this paper
• Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial

  2011cited by this paper
• EGFR pathway in advanced non-small cell lung cancer.

  2011cited by this paper
• Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial.

  2011cited by this paper
• Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer.

  2011influential reference
• Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy.

  2010cited by this paper
• Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

  2010cited by this paper
• Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

  2010cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer

  2009cited by this paper
• Anti-ganglioside anti-idiotypic monoclonal antibody-based cancer vaccine induces apoptosis and antiangiogenic effect in a metastatic lung carcinoma

  2009cited by this paper
• Emerging therapeutic targets in non-small cell lung cancer.

  2009cited by this paper
• A PHASE 3 TRIAL OF GVAX IMMUNOTHERAPY FOR PROSTATE CANCER VS. DOCETAXEL PLUS PREDNISONE IN ASYMPTOMATIC, CASTRATION-RESISTANT PROSTATE CANCER (CRPC)

  2009cited by this paper
• MAGE-A3 ANTIGEN-SPECIFIC CANCER IMMUNOTHERAPEUTIC (ASCI) AS ADJUVANT THERAPY IN RESECTED STAGE IB/II NON-SMALL CELL LUNG CANCER (NSCLC): FROM PROOF-OF-CONCEPT TO PHASE III TRIAL (MAGRIT)

  2009cited by this paper
• Cancer resistance to complement-dependent cytotoxicity (CDC): Problem-oriented research and development.

  2009cited by this paper
• Gangliosides in cell recognition and membrane protein regulation.

  2009cited by this paper
• PD-1 and its ligands in tolerance and immunity.

  2008cited by this paper
• Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures.

  2008cited by this paper
• Cancer immunotherapy targeting tumour-specific antigens: towards a new therapy for minimal residual disease

  2008cited by this paper
• Cancer Immunology

  2008cited by this paper
• Lactoferrin, a major defense protein of innate immunity, is a novel maturation factor for human dendritic cells

  2008cited by this paper
• A Phase II Study of Tg4010 (Mva-Muc1-Il2) in Association with Chemotherapy in Patients with Stage III/IV Non-small Cell Lung Cancer

  2008cited by this paper
• Effect of oral talactoferrin (TLF) on levels of cytokines involved in the Th1-mediated immune response in clinical studies

  2008cited by this paper
• Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.

  2008cited by this paper
• CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion.

  2008cited by this paper
• Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer.

  2008cited by this paper
• Immune surveillance of tumors.

  2007cited by this paper
• Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer

  2007cited by this paper
• 1E10 anti-idiotype vaccine in non-small cell lung cancer: Experience in stage IIIb/IV patients.

  2007cited by this paper
• L-BLP25: A Peptide Vaccine Strategy in Non–Small Cell Lung Cancer

  2007cited by this paper
• Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers

  2007cited by this paper
• Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer.

  2006cited by this paper
• A point mutation in the NFYC gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human squamous cell lung carcinoma

  2006cited by this paper
• Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.

  2006cited by this paper
• Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma

  2006cited by this paper
• Expression of multiple epigenetically regulated cancer/germline genes in nonsmall cell lung cancer

  2006cited by this paper
• Tumor infiltrating Foxp3+ regulatory T‐cells are associated with recurrence in pathologic stage I NSCLC patients

  2006cited by this paper
• Response to Comment on “Analysis of the Cellular Mechanism of Antitumor Responses and Autoimmunity in Patients Treated with CTLA-4 Blockade”

  2006cited by this paper
• Analysis of the Cellular Mechanism of Antitumor Responses and Autoimmunity in Patients Treated with CTLA-4 Blockade

  2005influential reference
• Cancer-Testis Genes Are Coordinately Expressed and Are Markers of Poor Outcome in Non–Small Cell Lung Cancer

  2005cited by this paper
• O-105 Pharmacogenomic study of docetaxel and cisplatin in patients with non-small cell lung cancer (NSCLC) stages IIIb (with malignant pleural effusion) and IV

  2005cited by this paper
• Immunosuppressive networks in the tumour environment and their therapeutic relevance

  2005cited by this paper
• Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer.

  2005cited by this paper
• Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.

  2005cited by this paper
• GM-CSF gene-transduced tumor vaccines.

  2005cited by this paper
• Elevated TGF-β1 Secretion and Down-Modulation of NKG2D Underlies Impaired NK Cytotoxicity in Cancer Patients1

  2004cited by this paper
• The three Es of cancer immunoediting.

  2004cited by this paper
• Elevated TGF-b1 Secretion and Downmodulation of NKG2D Underlies Impaired NK Cytotoxicity in Cancer Patients

  2004cited by this paper
• Melanoma associated antigen (MAGE)-A3 expression in Stages I and II non-small cell lung cancer: results of a multi-center study.

  2004cited by this paper
• Inhibitor of Apoptosis Proteins: Translating Basic Knowledge into Clinical Practice

  2004cited by this paper
• Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer.

  2004cited by this paper
• MUC1 immunobiology: from discovery to clinical applications.

  2004cited by this paper
• Circulating anti‐MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer

  2003cited by this paper
• Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen‐specific immunotherapy in patients with MUC1‐positive advanced cancer

  2003influential reference
• Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma.

  2003cited by this paper
• Immune escape of tumors: apoptosis resistance and tumor counterattack

  2002cited by this paper
• Tissue Microarray Evaluation of Melanoma Antigen E (MAGE) Tumor-Associated Antigen Expression: Potential Indications for Specific Immunotherapy and Prognostic Relevance in Squamous Cell Lung Carcinoma

  2002cited by this paper
• A point mutation in the alpha-actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma.

  2001cited by this paper
• Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance.

  2000influential reference
• Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer.

  2000cited by this paper
• A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma

  2000cited by this paper
• Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2

  1998cited by this paper
• Fas ligand and immune evasion

  1996cited by this paper
• Identification of MAGE-1 and MAGE-4 proteins in spermatogonia and primary spermatocytes of testis.

  1995cited by this paper
• A placebo-controlled randomized double-blind study of adjuvant intrapleural BCG in patients with resected T1N0, T1N1, or T2N0 squamous cell carcinoma, adenocarcinoma, or large cell carcinoma of the lung. LCSG Protocol 771.

  1994cited by this paper
• A Placebo-Controlled Randomized Double-Blind Study of Adjuvant Intrapleural BCG in Patients With Resected T1N0, T1N1, or T2N0 Squamous Cell Carcinoma, Adenocarcinoma, or Large Cell Carcinoma of the Lung: LCSG Protocol 771

  1994cited by this paper

• Vaccine-based therapeutic interventions in lung cancer management: A recent perspective

  2024cites this paper
• MALDI Mass Spectrometry Imaging Linked with Top-Down Proteomics as a Tool to Study the Non-Small-Cell Lung Cancer Tumor Microenvironment

  2019cites this paper
• Spectrum of Pharmacological Activity of Monoclonal Antibodies

  2019cites this paper
• In vitro study of the Polo‐like kinase 1 inhibitor volasertib in non‐small‐cell lung cancer reveals a role for the tumor suppressor p53

  2019cites this paper
• Screening a Broad Range of Solid and Haematological Tumour Types for CD70 Expression Using a Uniform IHC Methodology as Potential Patient Stratification Method

  2019cites this paper
• Targeting ubiquitin-proteasome pathway by natural, in particular polyphenols, anticancer agents: Lessons learned from clinical trials.

  2018cites this paper
• The changing face of cancer treatments

  2018cites this paper
• Relevance of small GTPase Rac1 pathway in drug and radio-resistance mechanisms: Opportunities in cancer therapeutics.

  2018cites this paper
• Combined immunotherapy of breast cancer with EGF and VEGF vaccines from DNA shuffling in a mouse model.

  2017cites this paper
• Activation of PGE2/EP2 and PGE2/EP4 signaling pathways positively regulate the level of PD-1 in infiltrating CD8+ T cells in patients with lung cancer.

  2017cites this paper
• Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy

  2017cites this paper
• Liquid Biopsy in Cancer Patients: The Hand Lens to Investigate Tumor Evolution

  2017cites this paper
• Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype.

  2016cites this paper
• Recent developments in the use of immunotherapy in non-small cell lung cancer

  2016cites this paper
• PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis

  2016cites this paper
• The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status

  2016cites this paper
• Racotumomab for treating lung cancer and pediatric refractory malignancies

  2016cites this paper
• Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy

  2016influential citation
• CD70: An emerging target in cancer immunotherapy.

  2015cites this paper
• Personalized Medicine: A Review with Regard to Biomarkers

  2015cites this paper
• The 2014 European Summit on Biomarkers : Biomarkers in Diagnostics

  2015cites this paper
• Inhibition of Tumor Growth and Immunomodulatory Effects of Flavonoids and Scutebarbatines of Scutellaria barbata D. Don in Lewis-Bearing C57BL/6 Mice

  2015cites this paper
• Molecular determinants of radiation response in non-small cell lung cancer.

  2015cites this paper
• Pharmacokinetics of crizotinib in NSCLC patients

  2015cites this paper
• Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer

  2015cites this paper
• Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced non-small cell lung cancer.

  2014cites this paper